Table 2.
Baseline Characteristics in Male Versus Female Patients
| Characteristic | Male (n = 118) | Female (n = 84) |
|---|---|---|
| Mean age, years (SD) | 64.0 (12.7) | 69.5 (11.3) |
| Baseline occlusion type, n (%) | ||
| BRVO/HRVO | 59 (50.0) | 56 (66.7) |
| CRVO | 59 (50.0) | 28 (33.3) |
| Mean BCVA, ETDRS letters (SD) | 52.2 (14.0) | 55.0 (11.6) |
| Patients with 20/200 or worse vision, n (%) | 22 (18.6) | 8 (9.5) |
| Mean CST, μm (SD) | 539.0 (177.5) | 508.6 (138.3) |
| Mean time since diagnosis of RVO, months (SD) | 1.7 (2.1) | 1.7 (1.7) |
| Prior therapies, n (%) | ||
| Intravitreal steroids | 7 (5.9) | 2 (2.4) |
| Laser photocoagulation | 1 (0.8) | 1 (1.2) |
| Comorbidities, n (%) | ||
| Open-angle glaucoma | 10 (8.5) | 7 (8.3) |
| Hypertension | 70 (59.3) | 61 (72.6) |
| Angina | 4 (3.4) | 3 (3.6) |
| Congestive heart failure | 2 (1.7) | 4 (4.8) |
| Diabetes mellitus | 18 (15.3) | 13 (15.5) |
BCVA best-corrected visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CST central subfield thickness, ETDRS Early Treatment Diabetic Retinopathy Study, HRVO hemiretinal vein occlusion, RVO retinal vein occlusion